No Data
Emerging markets stock digest: AVILEN surged significantly, with Immune Biosciences hitting the limit up.
Stalemate. On the 11th, after the close of trading, the performance for the fiscal year ending August 2024 was announced, and it has been in a stalemate even after starting to rise.
Hot stocks digest (morning session): JINSHD, KOZAIDOH HD, Bic Camera, etc.
Cosmos Pharmaceuticals <3349>: ¥7,729 (+¥409) rebounded significantly. The company announced its first-quarter financial results last weekend, with an operating profit of ¥11.6 billion, a 28.8% increase from the same period last year, exceeding the market consensus by approximately ¥2 billion. The gross profit margin for general food has shown significant improvement. The unchanged full-year plan is ¥31.6 billion, a 0.3% increase from the previous year, with a significant upside potential. Additionally, the same-store sales for September that were simultaneously announced decreased by 4.2% compared to the same month last year.
D&M Company --- decline, operating profit for the first quarter of the fiscal year ending in May 2025 increased by 18% compared to the same period last year, showing a solid performance.
Decreased. After the end of trading on the 11th, the performance of the first quarter of the fiscal year ending in May 2025 was announced. Revenue was 44.1 billion yen (+44.1% year-on-year), operating profit was 8.6 billion yen (+18.1% year-on-year), showing a solid performance. The increase in the number of debt-purchasing companies in the F&I service contributed to this, as well as the sale of large medical equipment in the C&Br service. In addition, preparations are underway to expand outsourcing services in the HR&OS service, anticipating increased revenue in the second quarter and beyond.
Ryohin Keikaku, operating profit up by 69.4% to 56.1 billion yen on August 24, financial estimates for August 25 showing a 2.0% decrease to 55 billion yen.
Ryohin Keikaku <7453> announced its financial results for the August 2024 period, with operating revenue increasing by 13.8% year-on-year to 661.677 million yen, and operating profit increasing by 69.4% to 56.135 million yen. Both operating revenue and each stage profit reached record highs. The improvement in operating gross profit margin was due to the effects of domestic price adjustments and the suppression of price reductions. For the August 2025 period, operating revenue increased by 10.9% year-on-year to 734 billion yen, while operating profit decreased by 2% to 55 billion yen.
Emerging markets outlook: Will the sluggish trading in the growth market continue, or will short-term funds flow into recent ipos?
In the thin trading, it is difficult to grasp the direction of the index, as emerging markets fell this week. During the same period, while the Nikkei Average was +2.51%, the Growth Market Index was -1.50%, and the Growth Market 250 Index was -1.39%, highlighting the weakness of the growth market. Similar to the main board market, at the beginning of the week, there was buying based on the rise of US stocks, but due to the yen depreciation and dollar appreciation, large-cap stocks were favored, resulting in a heavy upward trend after the buying wave. The trading value was 100 billion yen.
D&M Co: Presentation of financial results for the 1st quarter of the fiscal year ending May 2025
No Data
No Data